Foghorn Therapeutics (FHTX) Interest & Investment Income (2022 - 2026)

Foghorn Therapeutics' Interest & Investment Income history runs 5 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• In Q1 2026, Interest & Investment Income fell 35.29% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $7.8 million (down 35.86% YoY), while the FY2025 annual figure was $8.7 million, down 26.51% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $1.7 million, up from $1.7 million in the prior quarter.
• The five-year high for Interest & Investment Income was $3.5 million in Q3 2024, with the low at $235000.0 in Q1 2022.
• The 5-year median for Interest & Investment Income is $2.4 million (2024), against an average of $2.3 million.
• The sharpest annual moves came in 2023 and 2025: Interest & Investment Income jumped 1035.74% in 2023, then tumbled 44.7% in 2025.
• Foghorn Therapeutics' Interest & Investment Income stood at $2.4 million in 2022, then advanced by 11.95% to $2.7 million in 2023, then gained by 16.39% to $3.1 million in 2024, then sank by 44.7% to $1.7 million in 2025, then gained by 1.75% to $1.7 million in 2026.
• Business Quant data shows FHTX's Interest & Investment Income at $1.7 million in Q1 2026, $1.7 million in Q4 2025, and $2.0 million in Q3 2025.